New UC drug candidate ALTB-268 begins first human safety tests
NCT ID NCT07350577
First seen Jan 20, 2026 · Last updated May 15, 2026 · Updated 17 times
Summary
This study is an early test of a new drug called ALTB-268, which may one day treat ulcerative colitis. It involves 24 healthy adults who receive a single dose of the drug or a placebo to check for side effects and how the drug moves through the body. The goal is to make sure the drug is safe before testing it in people with the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ULCERATIVE COLITIS (UC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Syneos Health Clinical Research Services, LLC
Miami, Florida, 33136, United States
Conditions
Explore the condition pages connected to this study.